Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR and ONLY ADVR -- Ignore unavailable to you. Want to Upgrade?

To: Kingfisher who wrote (72)	9/26/2000 9:30:36 AM
From: Bernie Bildman	Respond to of 278

kingelvis, the following is from the recent SEC as regards the use of the words "Reticulose" and "Product R". In one place it seems as if they are saying they are the same, in another, it seems they are saying they are different:: (These are both taken out of context and post ONLY for display of the use of these two phrases) "The injunction obtained by the FDA prohibits, among other things, any shipment of Reticulose, now known as "Product R," "Our ability to generate substantial operating revenue depends upon our success in gaining FDA approval for the commercial use and distribution of Product R (the prior formulation of which was known as "Reticulose"). All of our research and development efforts have been devoted to the development of Product R."